AOD-9604: the tail end of growth hormone, on its own

AOD-9604 is a synthetic 16-residue peptide modelled on the tail end of human growth hormone. Its sequence copies hGH residues 177 to 191, the stretch that sits at the C-terminus of the intact 191-residue hormone, then adds a single tyrosine at the front and closes a disulfide bridge between its two cysteine residues. The design goal was narrow and deliberate: isolate the part of growth hormone that the research literature associates with lipid metabolism in preclinical models, while leaving out the larger regions responsible for the hormone's growth-promoting and glucose-related actions. In other words, it is a fragment chosen for one property and stripped of the rest, which is exactly what makes it useful as a laboratory probe rather than a stand-in for the whole hormone.

The molecule emerged from work at Monash University in Australia during the 1990s and was later carried forward commercially by Metabolic Pharmaceuticals. It built directly on earlier structural mapping by Frank Ng and colleagues, who traced the lipolytic character of growth hormone to its C-terminal domain rather than to the hormone as a whole. The natural fragment, hGH(177-191), had already been examined for its influence on fat-cell metabolism in rodents, so the research question was whether a slightly modified, better-behaved version could reproduce those observations reliably. Adding the N-terminal tyrosine gave a more tractable analogue that was easier to synthesise and characterise. Over the following two decades AOD-9604 became one of the most heavily documented growth-hormone fragments in the metabolic literature, which is part of why it still appears as a reference compound today.

The working hypothesis behind the molecule is simple to state. If the C-terminal region carries the signal that growth hormone uses to mobilise lipid, then a short peptide taken from that region might reproduce the lipid-metabolism effects on its own. In cultured adipocytes and in rodent adipose tissue, the fragment has been reported to increase lipolysis and to blunt lipogenesis, with several studies pointing to changes in beta-3 adrenergic signalling and in the expression of the genes that regulate how cells handle lipid. Some reports also describe shifts in the balance between fat storage and fat mobilisation at the level of enzyme activity. None of this amounts to a clean, single-pathway explanation, and that ambiguity is itself part of what researchers have tried to resolve.

A recurring and genuinely interesting question is whether AOD-9604 acts through the growth hormone receptor at all. Several reports found that its activity in fat tissue persisted in experimental systems where classical growth-hormone-receptor signalling was absent or blocked, and work in beta-3 adrenergic receptor knockout mice was used specifically to test whether that adrenergic pathway is required for the observed effects. The picture that emerged is of a fragment whose lipid-related activity looks at least partly independent of the intact hormone's principal receptor. That independence is not a footnote: it is the main reason the compound drew attention as a mechanistic tool. A peptide that separates one downstream effect of a hormone from the receptor normally credited with producing it is a useful object of study in its own right, regardless of any application.

Outside the metabolic setting, AOD-9604 has been examined in cartilage and connective-tissue models, where investigators looked at chondrocyte behaviour and markers of joint-tissue biology, sometimes in combination with other compounds. Chemically, the peptide is defined by its verified molecular formula and mass and by that single intramolecular disulfide bond, which links the two cysteines and constrains the backbone into a loop rather than leaving it as a free linear chain. The added N-terminal tyrosine is the one residue not present in the native hGH(177-191) sequence, and it is there to aid stability and detection rather than to change the core biology. These structural facts are what let the molecule be identified unambiguously and separated from the many other growth-hormone-derived fragments that circulate in the research supply chain.

The honest reading is that the preclinical file is far larger than the human one. An early-phase clinical program in metabolic research advanced through initial studies, but the reported effect sizes were modest and the compound did not progress the way its sponsors had hoped. A later attempt to position it as a food-ingredient additive did not clear United States regulatory review. Oral and other non-parenteral routes show poor bioavailability, which complicates any interpretation that assumes the molecule reaches its target intact. Much of the optimistic framing that surrounds AOD-9604 traces back to rodent data that has not reproduced cleanly at larger scale. The sensible posture is to read the mouse studies as mouse studies, hold the mechanism as provisional, and keep the compound firmly in the research-reference category.

For laboratory research use only. Not for human or veterinary use.

Verified molecule

• Sequence: YLRIVQCRSVEGSCGF (hGH(177-191) analogue with an N-terminal Tyr and a Cys-Cys disulfide)
• Molecular formula: C78H123N23O23S2
• Molecular weight: 1815.1 g/mol
• CAS number: 221231-10-3

Common questions

Is AOD-9604 a form of growth hormone?

No. It is a short synthetic peptide that copies only the final region of the growth hormone sequence, residues 177 to 191, plus one added tyrosine at the front. It lacks the large majority of the hormone, and in several experimental models its reported effects on lipid metabolism did not appear to depend on the growth hormone receptor. That is precisely why it is studied as a distinct fragment rather than as a substitute for the full molecule.

What does the disulfide bond do?

The two cysteine residues form an intramolecular bridge that folds the peptide into a constrained loop. This is not cosmetic: the loop is part of the molecule's defined identity and is reflected directly in its verified molecular formula and mass. A version without that bond would be a different chemical entity, which is one reason the disulfide is called out explicitly in the reference data.

Why is nearly all the evidence preclinical?

The bulk of the published work sits in cell cultures and in rodent models of lipid metabolism, with a smaller strand in joint-tissue biology. Human data are limited, and results from animal systems do not automatically carry across. Combined with the poor bioavailability of the peptide outside parenteral routes, that is why the compound is handled strictly as a research reference material rather than anything more.

References

1. Heffernan M, et al. Effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese mice. Endocrinology, 2001.
2. Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 2000.